Page 285 - Read Online

Page 14 of 14 Russo et al. Hepatoma Res 2018;4:25 I http://dx.doi.org/10.20517/2394-5079.2018.52

veteran patients with hepatocellular carcinoma. J Hepatol 2017;67:32-9.
48. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, Guyader D, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim
F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Leroy V, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Dharancy S,
Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis
C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Thibaut V, Salmon D, Ziol M, Sutton A, Pol S, Roudot-Thoraval F; ANRS
CO12 CirVir Group. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications.
Gastroenterology 2017;152:142-56.e2.
49. Petta S, Di Marco V, Bruno S, Enea M, Calvaruso V, Boccaccio V, Rossi S, Craxì A, Cammà C. Impact of virus eradication in patients with
compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. Liver Int 2016;36:1765-73.
50. Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Buxton J, Wong J, Tyndall T, Janjua NZ, BC-HTC Team. Impact of drug use and
opioid substitution therapy on hepatitis C reinfection: The BC Hepatitis Testers Cohort. Hepatology 2016;64:31A.
51. Camma C, Cabibbo G, Craxi A. Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol 2016;65:861-
2.
52. Alberti A, Piovesan S. Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: fact or fiction? Liver Int
2017;37:802-8.
53. Blanco JR, Rivero-Juarez A. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-
acting antiviral drugs: should we be worry about it? Expert Rev Anti Infect Ther 2016;14:993-6.